Study the efficacy of fosravuconazole as a potential new, safe, and affordable treatment for patients with eumycetoma
current phase of drug development
updated 1 Mar 2022
Treating eumycetoma (fungal mycetoma) is a challenge. The antifungals ketoconazole and itraconazole are currently the only therapies available, but they are expensive, not very effective, and have serious side effects. People with eumycetoma must often undergo multiple amputations, which sometimes result in death. Safe, effective antifungal treatments for eumycetoma that are appropriate for use in rural settings are urgently needed.
Fosravuconazole, an orally bioavailable azole developed for onychomycosis by Eisai Ltd (Japan), could be an effective and affordable treatment for eumycetoma. Its pharmacokinetic properties are favourable, and its toxicity is low. Fosravuconazole, a prodrug, is rapidly converted to ravuconazole, which has been shown to have potent in vitro activity against one of the causative agents of eumycetoma, M. mycetomatis.
In 2017, the Mycetoma Research Centre (MRC), a WHO Collaborating Centre in Khartoum, Sudan, began enrolling patients in the first-ever double-blind, randomized clinical trial for eumycetoma treatment. The trial is studying the efficacy of treating moderate-sized lesions with a weekly dose of fosravuconazole over a period of 12 months, compared to daily treatment with itraconazole, the current standard of care.
Fosravuconazole is also being evaluated by DNDi for Chagas disease.
News & press releases
Get our latest news, personal stories, research articles, and job opportunities.